LCM
TVTX icon

LionEye Capital Management’s Travere Therapeutics TVTX Stock Holding History

LionEye Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-303,500
Closed -$3.56M – 59
2014
Q2 		$3.56M Buy
+303,500
New +$4.11M 0.24% 43

Other funds holding TVTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Amici Capital New York $257M AUM 4.88% 1-Year Est. Return

LionEye Capital Management's TVTX Position: Q3 2014 in Review

LionEye Capital Management sold out of Travere Therapeutics (TVTX) in Q3 2014, closing a stake of 303,500 shares — an estimated $3.56M sold.

LionEye Capital Management first reported a position in TVTX in Q2 2014 and held it in 1 quarter. The position peaked at $3.56M in Q2 2014. 60 funds tracked by Wall St. Rank hold TVTX as of Q3 2014.

  • LionEye Capital Management reported no remaining Travere Therapeutics position as of Q3 2014 after selling out during the quarter.
  • LionEye Capital Management sold 303,500 Travere Therapeutics shares in Q3 2014, an estimated $3.56M.
  • LionEye Capital Management first reported a position in Travere Therapeutics in Q2 2014 and held it in 1 quarter.
  • LionEye Capital Management's Travere Therapeutics position peaked at $3.56M in Q2 2014.
  • 60 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2014.

Based on LionEye Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.